Potential New Applications of Sodium–Glucose Cotransporter-2 Inhibitors Across the Continuum of Cancer-Related Cardiovascular Toxicity
Sodium–glucose cotransporter-2 inhibitors (SGLT2i), initially developed for the management of type 2 diabetes mellitus, have demonstrated significant nephroprotective and cardioprotective effects. These benefits have led to their inclusion in heart failure (HF) management guidelines, irrespective of...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/6/857 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839653122620784640 |
|---|---|
| author | Agnieszka Maria Zebrowska Anna Borowiec |
| author_facet | Agnieszka Maria Zebrowska Anna Borowiec |
| author_sort | Agnieszka Maria Zebrowska |
| collection | DOAJ |
| description | Sodium–glucose cotransporter-2 inhibitors (SGLT2i), initially developed for the management of type 2 diabetes mellitus, have demonstrated significant nephroprotective and cardioprotective effects. These benefits have led to their inclusion in heart failure (HF) management guidelines, irrespective of glycemic status and left ventricular ejection fraction (LVEF). Various anticancer therapies, particularly anthracyclines, are associated with substantial cardiotoxicity risks, resulting in cancer therapy-related cardiovascular toxicity (CTR-CVT). Promising evidence from preclinical and observational studies indicates that SGLT2i may mitigate cardiotoxic effects of cancer therapy by alleviating LVEF decline, reducing HF incidence and hospitalizations, and lowering overall mortality. Moreover, improved survival has been reported in patients with various malignancies. The current review explores the potential applications of SGLT2i in the prevention of CTR-CVT, highlights their possible mechanisms of cardioprotection, discusses the published evidence, and emphasizes the need for the results from ongoing randomized controlled trials to establish SGLT2i efficacy and safety in cardio-oncology patients. |
| format | Article |
| id | doaj-art-f13e77cd3e444072b4401eb0f1f6f33d |
| institution | Matheson Library |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-f13e77cd3e444072b4401eb0f1f6f33d2025-06-25T14:17:44ZengMDPI AGPharmaceuticals1424-82472025-06-0118685710.3390/ph18060857Potential New Applications of Sodium–Glucose Cotransporter-2 Inhibitors Across the Continuum of Cancer-Related Cardiovascular ToxicityAgnieszka Maria Zebrowska0Anna Borowiec1Cardinal Stefan Wyszynski Institute of Cardiology, 04-628 Warsaw, PolandNon-Commercial Clinical Trials Outpatient Clinic, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandSodium–glucose cotransporter-2 inhibitors (SGLT2i), initially developed for the management of type 2 diabetes mellitus, have demonstrated significant nephroprotective and cardioprotective effects. These benefits have led to their inclusion in heart failure (HF) management guidelines, irrespective of glycemic status and left ventricular ejection fraction (LVEF). Various anticancer therapies, particularly anthracyclines, are associated with substantial cardiotoxicity risks, resulting in cancer therapy-related cardiovascular toxicity (CTR-CVT). Promising evidence from preclinical and observational studies indicates that SGLT2i may mitigate cardiotoxic effects of cancer therapy by alleviating LVEF decline, reducing HF incidence and hospitalizations, and lowering overall mortality. Moreover, improved survival has been reported in patients with various malignancies. The current review explores the potential applications of SGLT2i in the prevention of CTR-CVT, highlights their possible mechanisms of cardioprotection, discusses the published evidence, and emphasizes the need for the results from ongoing randomized controlled trials to establish SGLT2i efficacy and safety in cardio-oncology patients.https://www.mdpi.com/1424-8247/18/6/857sodium–glucose cotransporter-2 inhibitorscardiotoxicitycancer therapy-related cardiac dysfunctioncancer therapy-related cardiovascular toxicityanthracycline-induced cardiotoxicitycardioprotection |
| spellingShingle | Agnieszka Maria Zebrowska Anna Borowiec Potential New Applications of Sodium–Glucose Cotransporter-2 Inhibitors Across the Continuum of Cancer-Related Cardiovascular Toxicity Pharmaceuticals sodium–glucose cotransporter-2 inhibitors cardiotoxicity cancer therapy-related cardiac dysfunction cancer therapy-related cardiovascular toxicity anthracycline-induced cardiotoxicity cardioprotection |
| title | Potential New Applications of Sodium–Glucose Cotransporter-2 Inhibitors Across the Continuum of Cancer-Related Cardiovascular Toxicity |
| title_full | Potential New Applications of Sodium–Glucose Cotransporter-2 Inhibitors Across the Continuum of Cancer-Related Cardiovascular Toxicity |
| title_fullStr | Potential New Applications of Sodium–Glucose Cotransporter-2 Inhibitors Across the Continuum of Cancer-Related Cardiovascular Toxicity |
| title_full_unstemmed | Potential New Applications of Sodium–Glucose Cotransporter-2 Inhibitors Across the Continuum of Cancer-Related Cardiovascular Toxicity |
| title_short | Potential New Applications of Sodium–Glucose Cotransporter-2 Inhibitors Across the Continuum of Cancer-Related Cardiovascular Toxicity |
| title_sort | potential new applications of sodium glucose cotransporter 2 inhibitors across the continuum of cancer related cardiovascular toxicity |
| topic | sodium–glucose cotransporter-2 inhibitors cardiotoxicity cancer therapy-related cardiac dysfunction cancer therapy-related cardiovascular toxicity anthracycline-induced cardiotoxicity cardioprotection |
| url | https://www.mdpi.com/1424-8247/18/6/857 |
| work_keys_str_mv | AT agnieszkamariazebrowska potentialnewapplicationsofsodiumglucosecotransporter2inhibitorsacrossthecontinuumofcancerrelatedcardiovasculartoxicity AT annaborowiec potentialnewapplicationsofsodiumglucosecotransporter2inhibitorsacrossthecontinuumofcancerrelatedcardiovasculartoxicity |